Recent Posts

Post thread…


Rick succession plan - Eli Lilly

  • As a former employee, I’m literally laughing until tears are streaming down my face. How can you not get your medication covered for the plan you give employees? So, all the ZB patients will use Lilly Direct now? Wow, just wow!!

anonymous
May 17, 2025 at 07:33 AM
CEO sacking - Novo Nordisk

  • anonymous said:
    The failure here is not the recent performance that resulted in the stock decline but rather the decisions that were made years ago that severely underestimated the potential of semaglutide in obesity. Had the company really known what they had, we wouldn’t be in the no-win situation we are in now.

    We would’ve had supply from the start. We would gained preference earlier. It would have taken years not months for Zepbound to take over.

    Lars himself admitted as much a couple years ago during the peak of our supply issues. We are a diabetes company and we looked at Wegovy and obesity as a nice little add on. We totally underestimated the paradigm shifting potential that GLP-1 had.

    Since that decision we made mis-step after mis-step. We thought our way of doing it was the right away and neglected to innovate and all the while Lilly just kept marching on.

    You don’t need thousands of reps selling Wegovy. We launched it with a couple hundred. What you needed was supply. Support. Access. Innovation.

    But now it’s all too late. Nothing can be done now to change the trajectory of both Ozempic and Wegovy. The best we can do is hope that CagriSema or another asset we’ve acquired can compete.

    But again, Lilly is light years ahead of us in pipeline and their next generation meds look better than our own.

    Love Novo as a company, but I fear for our future.
    Click to expand...

    There is so much to dissect and poster you nailed it. SOV is so 2002, recall teams of 4 and people tripped over one another. We were on a wave and and it crashed. Look at the number of people we employ, doing what? Not even talking sales reps or field based--look at the people who are in home office- who are they?

    Also-Eco teams, innovation regions is not the answer. It is a disaster. Fear for future is real.

    The Town Hall call to action-EDGE selling and gain commitment? Competitive selling? Create a positive experience?

anonymous
May 17, 2025 at 07:33 AM
Giving notice in CMH - Eli Lilly

  • It depends- you may work the full 2 weeks or whatever you give them, but be prepared for everything to get cut off immediately, including the car, like the other poster states. Personally I would give a date that is a month out and they will most likely shorten that esp if you are staying in the industry in the same territory.

anonymous
May 17, 2025 at 07:28 AM
Zavzpret Dinner Programs - Pfizer

  • Is Zac secondary to neuter?

anonymous
May 17, 2025 at 07:22 AM
CEO sacking - Novo Nordisk

  • anonymous said:
    The failure here is not the recent performance that resulted in the stock decline but rather the decisions that were made years ago that severely underestimated the potential of semaglutide in obesity. Had the company really known what they had, we wouldn’t be in the no-win situation we are in now.

    We would’ve had supply from the start. We would gained preference earlier. It would have taken years not months for Zepbound to take over.

    Lars himself admitted as much a couple years ago during the peak of our supply issues. We are a diabetes company and we looked at Wegovy and obesity as a nice little add on. We totally underestimated the paradigm shifting potential that GLP-1 had.

    Since that decision we made mis-step after mis-step. We thought our way of doing it was the right away and neglected to innovate and all the while Lilly just kept marching on.

    You don’t need thousands of reps selling Wegovy. We launched it with a couple hundred. What you needed was supply. Support. Access. Innovation.

    But now it’s all too late. Nothing can be done now to change the trajectory of both Ozempic and Wegovy. The best we can do is hope that CagriSema or another asset we’ve acquired can compete.

    But again, Lilly is light years ahead of us in pipeline and their next generation meds look better than our own.

    Love Novo as a company, but I fear for our future.
    Click to expand...
    Agree with ya here 100%. I do think pushing Lars out like this was a big mistake as he was much beloved by the employees here. An intelligent and kind leader that you would follow to his next company. Hopefully he can just retire and enjoy life, I'm sure he's built up a bit of a nest egg by now :)

anonymous
May 17, 2025 at 07:18 AM
Top Bottom
Back
Post thread…